AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04284280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine vs Selective use of Human Milk Donor Fortifier
Description: Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
Study NCT01164865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE RepleniSH multipurpose disinfecting solution
Description: FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
Study NCT01816815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00762931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolve Stimulator and Proximity Lead
Description: An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
Study NCT01748331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluid restriction
Description: Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
Study NCT04425668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuing educational
Description: Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah.
Study NCT01366677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Three yoga classes per week for 8 weeks.
Study NCT00834652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50 mg once a day, which may be increased to 200 mg once a day
Study NCT00834652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: 50 mg once a day, which may be increased to 200 mg once a day
Study NCT00834652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
Study NCT01713231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose vitamin D (400IU per day)
Study NCT01713231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-dose vitamin D (2000 IU per day)
Study NCT03316378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: single dose, subcutaneous injection
Study NCT04894565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: physical therapy 24 hrs after surgery
Study NCT02326987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
Study NCT03176459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel + Bupivacaine
Description: EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
Study NCT03176459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
Study NCT01081314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
Study NCT01081314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
Study NCT01081314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Protocol
Description: A modified version of Prolonged Exposure therapy for PTSD
Study NCT03732261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and dietary
Description: The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
Study NCT02326987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
Study NCT00897169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
Study NCT00897169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euglycaemic hyperinsulinaemic clamp
Description: A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
Study NCT03507348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: visits of tocilizumab injection (every 4 weeks, up to 5 visits)
Description: every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
Study NCT03507348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-30
Description: Rituximab 375 mg/m2 at Day-30
Study NCT03507348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab 375 mg/m2 at Day-15 (only for donors living)
Description: Rituximab 375 mg/m2 at Day-15
Study NCT01033929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10 (C-Tb)
Description: rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
Study NCT02296476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib
Description: Administered orally in a fasted state once daily.
Study NCT00886730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Card
Description: Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover.
Study NCT00886730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Centered Brochure
Description: Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email.
Study NCT00886730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician's endorsement
Description: Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
Study NCT00495703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6-months of regular aerobic exercise
Study NCT00495703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 6-months of behavioral strategies to aid memory/cognition
Study NCT02475421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: One hour glucagon-clamp followed by one hour of blood sampling
Study NCT03348124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children - what does it involve?
Description: Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling.
Study NCT03789981 — intervention group
Intervention type: GENETIC
Intervention: Immunogenic profile
Description: RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
Study NCT00786162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-enabled automated self-management program
Description: An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
Study NCT00786162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP cuff at workplace
Description: Provided BP cuff for communal use at the worksite
Study NCT03698279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT03698279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT03698279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT00490802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal Oxytocin
Study NCT00490802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT03167034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study NCT03698279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)
Description: Pharmaceutical form: Solution for injection Route of administration: IM
Study NCT03698279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Description: Pharmaceutical form: Solution for injection Route of administration: IM
Study NCT03507348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transplant Day-0
Description: TRANSPLANTATION
Study NCT03583229 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 75mg
Description: 7 days treatment with 75 mg aspirin daily.
Study NCT03181698 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls
Study NCT01164865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care contact lens care system
Description: FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
Study NCT03167034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study NCT03930225 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma Directed Psycho-educational Intervention program
Description: psycho-educational intervention with emphasis on Stigma
Study NCT03930225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Directed Psycho-educational Intervention program
Description: psycho-educational intervention with emphasis on Stigma
Study NCT01164865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
Study NCT02070302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
Study NCT02070302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal Saline) divided into 2 injections of .4cc each
Study NCT04254939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3007 (BLU-285)
Description: A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.
Study NCT03358784 — intervention group
Intervention type: PROCEDURE
Intervention: Hemi-shoulder Arthroplasty
Description: Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
Study NCT03358784 — intervention group
Intervention type: PROCEDURE
Intervention: PHILOS Plate
Description: PHILOS plate treating three or four-part fractures of proximal humerus
Study NCT03704402 — intervention group
Intervention type: OTHER
Intervention: Alcohol policy
Description: Introduction of new mutual alcohol policy
Study NCT03532113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updating
Description: Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
Study NCT03532113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibition
Description: Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
Study NCT03532113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General knowledge
Description: General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
Study NCT03583229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75mg
Description: 7 days treatment with 75 mg aspirin daily.
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered IV
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT03086369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02297061 — intervention group
Intervention type: BIOLOGICAL
Intervention: Thrombelastography analysis (TEG)
Description: TEG analysis is performed on admission
Study NCT05049434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe
Study NCT05049434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 5ml prefilled syringe
Study NCT00683696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Description: All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
Study NCT00683696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Description: All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
Study NCT06281054 — intervention group
Intervention type: PROCEDURE
Intervention: Revascularization
Description: Performing PCI or CABG
Study NCT01154985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 3x Placebo capsules three times a day (TID) for 365 days
Study NCT01154985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-E 300 mg capsule
Description: 2x 300 mg capsules + placebo capsule TID for 365 days
Study NCT01154985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-E 300 mg capsule
Description: 3x 300 mg capsules TID for 365 days
Study NCT00962234 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Description: Up to 4 blood draws will be required, in the amount of about 10 mL each
Study NCT00962234 — intervention group
Intervention type: BIOLOGICAL
Intervention: Oral administration of stable isotope (deuterium)
Description: 1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
Study NCT00962234 — intervention group
Intervention type: PROCEDURE
Intervention: Metabolic rate testing
Description: Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
Study NCT02306954 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose IL-2
Description: High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
Study NCT02306954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose IL-2
Description: High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
Study NCT02306954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
Study NCT04339348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal misoprostol
Description: vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
Study NCT04339348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine Topical cream
Description: Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion